Clinical Research Directory
Browse clinical research sites, groups, and studies.
Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years
Sponsor: National Liver Institute, Egypt
Summary
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years. Younger children are still on the wait list for treatment. The current study aimed to study the efficacy and safety of combined sofosbuvir (SOF)/daclatasvir (DCV) in children with hepatitis C virus infection aged 6-18 years.
Official title: Safety and Efficacy of Sofosbuvir / Daclatasvir in Children With HCV Aged 6-18 Years
Key Details
Gender
All
Age Range
6 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
42
Start Date
2023-12-18
Completion Date
2024-07-25
Last Updated
2026-10-30
Healthy Volunteers
No
Conditions
Interventions
Sofosbuvir/Daclatasvir
Patients weighted less than 35 kg receive oral daily dose of Sofosbuvir/Daclatasvir (200/30 mg) daily for 12 weeks. Patients weighted more than or equal to 35 kg receive oral daily dose of Sofosbuvir/Daclatasvir (400/60 mg) daily for 12 weeks
Locations (1)
Pediatric Hepatology, Gastroentrology and Nutrition Department, National Liver Institute, Menoufia University
Cairo, Menoufia, Egypt